GlassScriptPhysician profile
Mark W Sornson
NPI 1629189550
$3,214.97
in general payments reported to CMS, 2019-2025
19 companies · $1,573 in 2025
The $1,573 reported for 2025 was more than what 84% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.36 · 2021: $121 · 2022: $138 · 2023: $327 · 2024: $1,036 · 2025: $1,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,936.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $764.42 | 2021-2025 | |
| Incyte Corporation | $556.21 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $337.20 | 2023-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $253.91 | 2024-2025 | |
| Leo Pharma INC. | $216.08 | 2024-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $186.68 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $168.12 | 2023-2025 | Libtayo, Dupixent |
| Abbvie INC. | $151.77 | 2024-2025 | |
| Janssen Biotech, INC. | $124.20 | 2023-2025 | Tremfya |
| Ucb, INC. | $108.39 | 2025 | Bimzelx |
| Galderma Laboratories, L.P. | $75.43 | 2023-2025 | Nemluvio |
| Amgen INC. | $55.51 | 2023-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.40 | 2024 | Spevigo |
| Convatec INC. | $43.70 | 2025 | |
| Pfizer INC. | $42.84 | 2024-2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hill Dermaceuticals, INC. | $25.01 | 2025 | Tolak |
| Journey Medical Corporation | $21.74 | 2025 | |
| Dusa Pharmaceuticals, INC. | $20.36 | 2019 | |
| Dermavant Sciences, INC. | $15.00 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sornson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.